This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
NVOPositive Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change HIMSPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
by Zacks Equity Research
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
BMYNegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
AZNNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs medical pharmaceuticals
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2
by Nalak Das
Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.
TRINegative Net Change EXELPositive Net Change WWDNegative Net Change RGLDPositive Net Change SFMNegative Net Change
aerospace biotechs business-services gold retail
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
by Zacks Equity Research
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
RHHBYNegative Net Change NVOPositive Net Change BAYRYNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends INCY's Application for Opzelura Label Expansion
by Zacks Equity Research
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
GSKNegative Net Change BAYRYNegative Net Change INCYNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
JNJNegative Net Change ABBVNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs medical pharmaceuticals
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
by Zacks Equity Research
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
BMYNegative Net Change BNTXNegative Net Change CVACNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
BMYNegative Net Change PFENegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
by Zacks Equity Research
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
GSKNegative Net Change NVSNegative Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
by Zacks Equity Research
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
INCYNegative Net Change EXELPositive Net Change AMRNPositive Net Change PBYINegative Net Change
biotechs
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
by Ahan Chakraborty
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
SNYNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical oncology-screening pharmaceuticals
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
by Sundeep Ganoria
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
NVSNegative Net Change BMYNegative Net Change VRTXNegative Net Change BEAMNegative Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
GSKNegative Net Change NVOPositive Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
LLYNegative Net Change BEAMNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing medical pharmaceuticals
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
by Zacks Equity Research
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
BIIBNegative Net Change SUPNNegative Net Change
biotechs
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
SNYNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
by Zacks Equity Research
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
BAYRYNegative Net Change QGENNegative Net Change INCYNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
by Zacks Equity Research
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
TEVAPositive Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
RHHBYNegative Net Change ABBVNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs medical pharmaceuticals
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
by Zacks Equity Research
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
GRFSNegative Net Change ADMANo Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals